| Name | Ursodeoxycholic acid |
| Description | Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5). Ursodeoxycholic acid inhibits cholesterol absorption and is used to dissolve gallstones. |
| In vitro | METHODS: Ovarian cancer cell line A2780 and cisplatin-resistant cell line A2780 were treated with Ursodeoxycholic acid (300 nM) for 4 hours, and the cell growth inhibition was detected by MTT assay.
RESULTS: Ursodeoxycholic acid inhibited the growth of ovarian cancer A2780 cells (IC50=300 nM) and cisplatin-resistant A2780 cells (IC50=300 nM). [1]
METHODS: Colorectal cancer cells SW620 and HCT116 were treated with Ursodeoxycholic acid (0, 0.00625, 0.0125, 0.025, 0.05, 0.1 mg/mL) for 24 hours, and MTT assay was used to detect the inhibitory effect of ursodeoxycholic acid on cell growth.
RESULTS: Ursodeoxycholic acid inhibited the growth of colorectal cancer cells SW620 (IC50=0.02 mg/mL) and HCT116 (IC50=0.016 mg/mL). [2] |
| In vivo | METHODS: To study the effect of Ursodeoxycholic acid on body weight, Ursodeoxycholic acid (50, 150, and 450 mg/kg) was administered orally to mice for 21 days.
RESULTS: Significant weight loss was observed within a week in the groups of mice receiving 50 and 450 mg/kg doses. At the 50 mg/kg dose, this weight loss persisted throughout the experiment. At a dose of 450 mg/kg, weight loss was initially observed during the first and third weeks of Ursodeoxycholic acid administration. At the 150 mg/kg dose, there was no significant difference in body weight compared to untreated mice. [3] |
| Storage | Keep away from moisture | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 73 mg/mL (185.95 mM), Sonication is recommended.
DMSO : 255 mg/mL (649.57 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (12.74 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Ursodeoxycholic acid | Ursodeoxycholate | TGR5 | secondary bile acid | PotassiumChannel | Potassium Channel | oral | NR1H4 | lipid metabolism | intestinal barrier integrity | Inhibitor | inhibit | hepatic | G-protein coupled receptor 19 | GPCR19 | GPBAR1 | gastrointestinal diseases | G protein-coupled Bile Acid Receptor 1 | FXR | EndogenousMetabolite | Endogenous Metabolite | Bile salt export pump |
| Inhibitors Related | Sucrose | Aceglutamide | Nicotinamide riboside malate | DL-Lysine | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Formamide | Glycerol | Thymidine | Corn starch | Hyaluronic acid sodium (MW 20 kDa) | Gluconate Calcium |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Pain-Related Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Natural Product Library for HTS | Bitter Compound library | Human Endogenous Metabolite Library | Gut Microbial Metabolite Library | Anti-Cancer Drug Library |
United States
